Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1 | Q15116 | 12/20 | 0.44 |
| ▸ | CD274 | Q9NZQ7 | 12/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | RORC | P51449 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18071765 | 1.00 | PDCD1 (0.44) | PDCD1CD274S1PR1MAOBRORC | |
| SCHEMBL18046838 | 0.90 | PDCD1 (0.44) | PDCD1CD274S1PR1MAOBRORC | |
| SCHEMBL18046841 | 0.90 | PDCD1 (0.44) | PDCD1CD274S1PR1MAOBRORC | |
| SCHEMBL21236928 | 0.88 | S1PR1 (0.43) | PDCD1CD274S1PR1 | |
| SCHEMBL18046579 | 0.87 | HDAC4 (0.43) | PDCD1CD274S1PR1MAOB | |
| SCHEMBL18046577 | 0.87 | HDAC4 (0.43) | PDCD1CD274S1PR1MAOB | |
| SCHEMBL30827716 | 0.87 | HDAC4 (0.43) | PDCD1CD274S1PR1MAOB | |
| SCHEMBL18069276 | 0.85 | PDCD1 (0.43) | PDCD1CD274FFAR1PPARG | |
| SCHEMBL18047218 | 0.80 | RXFP1 (0.53) | MAOBFFAR1 | |
| SCHEMBL18047219 | 0.80 | RXFP1 (0.53) | MAOBFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11919839-B2 | Alpha-cinnamide compounds and compositions as HDAC8 inhibitors | VALO HEALTH, INC. (US) | 2024-03-05 | — | — | US | disclosed |
| US-20220073452-A1 | ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS | VALO HEALTH, INC. | 2022-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220073452-A1 | ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS | HDAC8, HDAC7, HDAC1 | PDCD1 1035/4885CD274 2446/4885S1PR1 2111/4885 |
| US-11919839-B2 | Alpha-cinnamide compounds and compositions as HDAC8 inhibitors | HDAC8, HDAC7, HDAC1 | PDCD1 1035/4885CD274 2446/4885S1PR1 2111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.